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Abstract 
The role that heparanase plays during metastasis and angiogenesis in tumours makes it an 
attractive target for cancer therapeutics. Despite this enzyme’s significance, most of the 
assays developed to measure its activity are complex. Moreover, they usually rely upon 
labelling variable preparations of the natural substrate heparan sulfate which makes 
comparisons across studies precarious. To overcome these problems, we have developed a 
convenient assay based on the cleavage of the synthetic heparin oligosaccharide 
fondaparinux. The assay measures the appearance of the disaccharide product of heparanase-
catalysed fondaparinux cleavage colorimetrically using the tetrazolium salt WST-1. Because 
this assay has a homogenous substrate with a single point of cleavage, the kinetics of the 
enzyme can be reliably characterised giving a Km of 46 µM and a kcat of 3.5 s-1 with 
fondaparinux as substrate. The inhibition of heparanase by the published inhibitor, PI-88, was 
also studied and the Ki of 7.9 nM determined. The simplicity and robustness of this method 
should, not only, greatly assist routine assay of heparanase activity, but could also be adapted 
for high-throughput screening of compound libraries with the data generated being directly 
comparable across studies.  
 
Keywords: heparanase, fondaparinux, colorimetric assay, heparan sulfate, enzyme kinetics. 
 
Introduction 
The enzyme heparanase is an endo-β-glucuronidase that cleaves heparan sulfate (HS) in the 
extracellular matrix (ECM) and basement membranes and thus facilitates metastasis of 
tumour cells and vascular remodelling associated with angiogenesis [1-3]. It also liberates 
angiogenic growth factors from the ECM and thereby induces an angiogenic response in vivo 
[4,5]. Heparanase is preferentially expressed in tumours and its upregulation correlates with 
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increased tumour vascularity and poor post-operative survival of cancer patients [6-8]. It is 
thus an attractive target for the development of cancer drugs with antiangiogenic and 
antimetastatic activity [9,10]. Although identified over two decades ago as a potential 
therapeutic target for cancer [11,12] for much of the intervening period heparanase research 
has been significantly restricted by the lack of a simple, accurate and robust assay for enzyme 
activity.  Various assays for heparanase activity have been developed over the years with a 
recent proliferation of assays, [13-17] including commercially available kits, [18,19] 
highlighting the growth in interest in this protein. Most assays use HS or heparin preparations 
as substrate and generally require prior labelling with radioisotopes, fluorescent labels or 
biotin to allow detection. These assays are also complicated by the fact that the HS/heparin 
fragments produced by heparanase catalysis may be inhibitors of the enzyme. Furthermore, 
most only produce semi-quantitative data making comparisons across studies difficult.  
Two assays have recently been developed which utilise a homogeneous 
oligosaccharide substrate of relatively low molecular weight. The substrate for these assays is 
fondaparinux (1, Figure 1), the fully synthetic methyl glycoside of the antithrombin III 
(ATIII)-activating pentasaccharide sequence of heparin [20]. These assays build on earlier 
studies showing that a heparin-derived octasaccharide containing the ATIII-binding sequence 
is cleaved by heparanase, [21] but make use of a commercially available substrate which 
avoids the low yielding and laborious total syntheses associated with other HS 
oligosaccharide substrates for heparanase [22,23]. In the first assay, heparanase activity is 
determined by measuring the change in anticoagulant activity following the cleavage of 
substrate using a standard chromogenic assay for anti-factor Xa activity [24]. The second 
assay utilises an LC-MS method for detecting and quantifying the oligosaccharide cleavage 
products of the reaction (2 and 3) using an internal heparin disaccharide as the standard [25]. 
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Whilst this assay represents a significant advance in this area, the amount of protein 
consumed per assay is relatively high and the assay procedure is labour intensive.  
In light of the above limitations, we sought to develop an improved assay using 
commercially available pentasaccharide 1 as the substrate and based on the detection of the 
newly formed reducing disaccharide 2. The quantification of newly formed reducing ends has 
long been used as a means to determine the enzymatic activity of various glycosidases and, in 
fact, the dye Tetrazolium Blue, was previously used in this fashion to assay heparanase 
activity using HS as the substrate [26]. Here we describe the resulting assay which uses 
colorimetric quantification, allows kinetic analysis and could be used for high-throughput 
screening of compound libraries to detect heparanase inhibitors in the development of cancer 
therapeutics.  
 
Materials and Methods 
 
Materials 
Unless otherwise stated, all reagents were obtained from Sigma-Aldrich. Assays were carried 
out in 96 well microplates (Costar 9018 EIA/RIA, Corning) which had been pre-treated with a 
solution of 4% BSA in phosphate-buffered saline containing 0.05% Tween 20 (PBST) for 2 h 
at 37°C. The plates were then washed three times with PBST and shaken dry. Pre-treated 
plates were stored at 4°C for up to 2 weeks before use.  
 
Recombinant human heparanase was expressed in insect cells [27] and then purified 
from the cell media into which it had been secreted. The media was clarified by centrifugation 
at 17,700 g at 4°C for 30 min before being loaded onto a 100 mL heparin sepharose column 
(GE Healthcare) pre-equilibrated to 20 mM sodium phosphate pH 7.5. The column was eluted 
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with a series of three 150 mL NaCl concentration steps in the same phosphate buffer: 0.3, 0.6 
and 0.8 M. Heparanase containing fractions eluting in the 0.8 M step were pooled (typically 
70 mL) and dialysed against 2 L of 10 mM sodium phosphate pH 7.0 at 4°C for 20 h. This 
material was then loaded onto a 55 mL Source 30S column (GE Healthcare) pre-equilibrated 
to 20 mM sodium phosphate pH 7.0 and eluted with a 900 mL linear NaCl gradient of 0-0.6 
M in the same buffer. Fractions containing pure heparanase, determined by silver staining of 
SDS-PAGE, were pooled, dialysed into 10 mM sodium phosphate pH 7.0, concentrated using 
centriplus concentrating devices (Millipore) and stored at -80°C until use.  
 
Assay method 
Assay solutions (100 µL) comprised 40 mM sodium acetate buffer pH 5.0, 100 mM 
fondaparinux (GlaxoSmithKline) with or without inhibitor PI-88. Heparanase was added to a 
final concentration of 140 pM, unless stated otherwise, to start the assay. The plates were 
sealed with adhesive tape and incubated at 37ºC for 2-24 h before the assays were stopped by 
the addition of 100 µL of a solution containing 1.69 mM 4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1, Auspep, Melbourne, 
Australia) in 0.1 M NaOH. The plates were resealed with adhesive tape and developed at 
60ºC for 60 min and the absorbance was measured at 584 nm (Fluostar, BMG Labtech). In 
each plate, a standard curve constructed with D-galactose as the reducing sugar standard was 
prepared in the same buffer and volume over the range of 2 to 100 µM.  In the case of PI-88, 
the IC50 value was determined and converted to a Ki using the method of Cheng and Prusoff 
[28]. All curve fitting, whether to determine Michaelis-Menten constants or IC50, was done 
using Biaevaluation software 4.1 (Biacore).  
 
Results and Discussion 
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Selection of reducing end reagent 
A variety of compounds were trialled to find the most suitable reagent to quantify the 
reducing disaccharide 2 formed by heparanase cleavage of the synthetic substrate 1. The best 
results, in terms of sensitivity and stability of the end product, were obtained with the water-
soluble tetrazolium salt WST-1. When reacted with a reducing sugar, WST-1 gave a response 
approximately twice that of Nitrotetrazolium Blue (Figure 1 in supplementary material) and 
because it formed a water-soluble formazan product no precipitate was formed, unlike other 
reagents such as Tetrazolium Blue and Nitrotetrazolium Blue. 
Complete digestion of 1 was accomplished by incubation with 10 nM heparanase in 
40 mM sodium acetate buffer pH 5.0 at 37°C for 24 h. Comparison of the WST-1 standard 
curves of D-galactose and cleaved 1 revealed that the disaccharide product of heparanase 
catalysis 2 produces a very similar absorbance to that of D-galactose (Figure 2). This is 
consistent with our expected yield of one reducing end per molecule of 1 cleaved by 
heparanase. Moreover, it provides us with a convenient standard (D-galactose) to allow the 
molar quantification of heparanase activity.  
 
Testing the assay 
Having established that the product of heparanase cleavage of 1 can be quantified 
using WST-1, experiments were conducted to confirm that the velocity of heparanase 
catalysis could be quantified using this method. First, the linearity of heparanase-dependant 
product formation over time was assessed by initiating numerous identical assays and 
stopping them at different times, ranging from 2 to 24 h. Similar experiments were conducted 
at different heparanase concentrations. The rate of product formation and, therefore, 
heparanase-catalysed 1 cleavage was linear up to 24 h for the range of heparanase 
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concentrations, 56 to 224 pM (Figure 3). This indicates that the assays are not substrate 
limiting, nor are they being inhibited by product accumulation, nor is heparanase stability 
affecting the results.  
The slopes of the linear regressions fitted to the data in Figure 3 indicate that the rate 
of 1 cleavage is proportional to the amount of heparanase added but to confirm this, further 
experiments were conducted. The results of the two sets of experiments indicate that the assay 
is heparanase dependent at least up to 22.4 fmol/assay (or 224 pM) as shown by the linear 
response of measured velocity with respect to enzyme concentration (Figure 4).  
 
Kinetic studies 
This heparanase assay allows kinetic analysis of the enzyme and its inhibitors, 
something usually not possible with previous assays. Using this assay, the substrate 
dependency of heparanase activity was examined and found to conform to Michaelis-Menten 
kinetics (Figure 5). The Km (46 ± 14 µM) and kcat (from Vmax, 3.5 ± 0.3 s-1) for heparanase-
catalysed 1 cleavage were determined by fitting the Michaelis-Menten equation to this data. 
The Km was previously reported to be 33 µM [29] but upon further analysis the result of 46 
µM was determined. This is significantly higher than the Km published for HS, 1.64 µM 
determined using the Microcon size exclusion assay [30], indicating that heparanase has a 
lower affinity for 1 than HS. Such a conclusion is consistent with previous observations that 
an oligosaccharide in which the 3-O-sulfo group on the central D-glucosamine residue of 1 is 
replaced with H, and which represents a sequence more commonly found in HS, significantly 
increases heparanase activity [23].  
The assay was tested by measuring the heparanase inhibition of PI-88, a competitive 
inhibitor of the enzyme [30]. The Ki determined for PI-88 was 7.9 ± 0.6 nM (Figure 6) which 
is considerably lower than the value of 240 ± 30 nM obtained using the Microcon assay [30]. 
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This difference is probably due to loss of PI-88 onto BSA which is added to the Microcon 
assay as a carrier to stabilise heparanase. BSA, however, is not required in the sample mixture 
of this assay making it more suitable for screening inhibitors because it will reduce the 
number of false negative results caused by compound loss onto carrier proteins. This assay 
has been designed to measure heparanase activity in well characterised samples and should 
excel in screening for heparanase inhibitors and in examining the kinetics of the enzyme. It 
may not be suitable for assaying some crude biological samples for heparanase because there 
may be components in these samples that interfere with the WST-1 detection and lead to 
erroneous results.  
 
Conclusion 
This report describes a simple, accurate and robust biochemical assay for heparanase activity 
that uses a commercially available, homogeneous substrate (fondaparinux) with a single 
enzymatic cleavage point and, thus, does not have the problems associated with using HS-
based assays. Detection is easily carried out by incubation with the water-soluble tetrazolium 
salt WST-1, which reacts with the newly created reducing disaccharide to produce a blue 
colour. The assay is suitable for testing heparanase inhibitors and could easily be adapted for 
use in high-throughput screening applications. Moreover, if widely adopted its use will allow 
the direct comparison of inhibitors by the determination of their Ki values. 
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nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate.  
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Figure Legends 
 
Figure 1. Cleavage of fondaparinux (1) by heparanase to produce the reducing disaccharide 
(2) and the non-reducing trisaccharide (3). 
Figure 2. Comparison of the absorbance responses at 584 nm obtained following reaction of 
WST-1 with D-galactose and disaccharide (2) formed from complete digestion of 
fondaparinux with 10 nM heparanase at 37ºC for 24 h. Error bars are SE (n = 4). 
Figure 3. Time course of fondaparinux cleavage at seven heparanase concentrations. Assays 
(100 µL) comprised 40 mM sodium acetate pH 5.0, 100 µM fondaparinux and indicated 
heparanase concentrations at 37ºC for indicated periods of time. Error bars are SE (n = 6 to 8). 
Figure 4. Measured fondaparinux cleavage velocity is proportional to heparanase content. 
Slope data from Figure 3 in open symbols. Additional data in solid symbols are means of 
three replicates assayed at 37ºC for 20 h (error bars are SE). Assays (100 µL) comprised 40 
mM sodium acetate pH 5.0, 100 µM fondaparinux and indicated heparanase contents at 37ºC.   
Figure 5. Velocity of fondaparinux cleavage by heparanase conforms to Michaelis-Menten 
kinetics. Curve fit to data estimates the Km at 46 ± 14 µM and Vmax at 3.5 ± 0.3 fmol fmol-1 s-1 
(Biaevaluation software). Assays (100 µL) comprised 40 mM sodium acetate pH 5.0, 
indicated fondaparinux concentrations and 140 pM heparanase at 37ºC for 20 h. Error bars are 
SE (n = 4 or 5).   
Figure 6. Inhibition of heparanase by the competitive inhibitor PI-88. Curve fit to data gives 
an IC50 of 25 ± 2 nM (Biaevaluation software) which was converted to a Ki of 7.9 ± 0.6 nM 
using the method of Cheng and Prusoff [28]. Assays (100 µL) comprised 40 mM sodium 
acetate pH 5.0, 100 µM fondaparinux, 140 pM heparanase and indicated PI-88 concentrations 
at 37ºC for 20 h. Data are expressed as % relative to controls containing no PI-88. Error bars 
are SE (n = 4).  
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